Warshawsky I, Schwartz A L
Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.
Eur J Cell Biol. 1996 Feb;69(2):156-65.
The low density lipoprotein receptor-related protein (LRP) has been proposed to function as an endocytosis receptor for chylomicron remnants and protease-inhibitor complexes so that these particles can be cleared from the plasma or extracellular fluid. The kidney glycoprotein 330 (gp330) may have an analogous role to LRP in the kidney. A 39-kDa protein which copurifies with LRP and gp330 inhibits the binding and/or cellular uptake of ligands to these receptors and may regulate LRP and gp330 activity in vivo. Recently, LRP has been immunochemically localized to endothelial and vascular smooth muscle cells. In the present study, the biology of the 39-kDa protein was studied in cultured endothelial cells and vascular smooth muscle cells. The 39-kDa protein is synthesized by both cell types and has an average half-life of 15 hours. Immunofluorescence shows the major part of the 39-kDa protein has an intracellular localization with enrichment in the perinuclear region. Tissue-type plasminogen activator (t-PA), a plasma serine protease that binds specifically and with high affinity to LRP on hepatoma cells, also binds to endothelial cells and vascular smooth muscle cells. 125I-t-PA binding to both cell types is inhibited by the 39-kDa protein. However, only the endothelial cells are capable of rapidly internalizing and degrading 125I-t-PA. These data thus suggest that LRP may function as a clearance receptor for t-PA on endothelial cells.
低密度脂蛋白受体相关蛋白(LRP)被认为可作为乳糜微粒残粒和蛋白酶抑制剂复合物的内吞受体,从而使这些颗粒能从血浆或细胞外液中清除。肾糖蛋白330(gp330)在肾脏中可能具有与LRP类似的作用。一种与LRP和gp330共纯化的39 kDa蛋白可抑制配体与这些受体的结合和/或细胞摄取,并且可能在体内调节LRP和gp330的活性。最近,LRP已通过免疫化学方法定位到内皮细胞和血管平滑肌细胞。在本研究中,对培养的内皮细胞和血管平滑肌细胞中39 kDa蛋白的生物学特性进行了研究。两种细胞类型均可合成39 kDa蛋白,其平均半衰期为15小时。免疫荧光显示,39 kDa蛋白的主要部分定位于细胞内,在核周区域富集。组织型纤溶酶原激活剂(t-PA)是一种血浆丝氨酸蛋白酶,可在肝癌细胞上特异性且高亲和力地与LRP结合,它也可与内皮细胞和血管平滑肌细胞结合。39 kDa蛋白可抑制125I-t-PA与这两种细胞类型的结合。然而,只有内皮细胞能够快速内化和降解125I-t-PA。因此,这些数据表明LRP可能在内皮细胞上作为t-PA的清除受体发挥作用。